share_log

研报掘金丨国盛证券:爱博医疗龙晶PR获批,维持“买入”评级

Research Reports Mining丨Guosheng Securities: Eyebright Medical Technology (Beijing) Co., Ltd. Longjing PR approved, maintaining a Buy rating.

Gelonghui Finance ·  Jan 8 17:04

Guosheng Securities' Research Reports point out that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) has received approval for the III class registration certificate for its intraocular lens and is now on the market. Longjing PR is the first domestically developed posterior chamber intraocular lens, innovatively using Balacrylic balanced acrylic material, featuring a unique aspherical double concave design with a wide-open peripheral arch, reducing the risk of peripheral contact with the artificial lens. The results of the 5-year clinical trials have been released, and multidimensional indicators show that Longjing PR outperforms ICL. Maintain a Buy rating.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment